Among chemotherapeutic agents, melphalan is the only alkylating drug reported to utilize LAT1, showing some efficacy in experimental brain cancer models [196,197,198] but ultimately failing in GBM clinical trials [199]. Here, SLC7A5 is linked to brain cancer.